Nature

MUC1 is a novel regulator of ErbB1 receptor trafficking

ErbB receptors are key regulators of cell survival and growth in normal and transformed tissues. The oncogenic glycoprotein MUC1 is a binding partner and substrate for erbB1 and MUC1 expression can ...
Nature

MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors

Pancreatic cancer is the most lethal malignancy, which is usually diagnosed at an advanced state for which there are few or no effective therapies. The incidence rates are nearly equal to the ...
ascopubs.org

Ablating MUC1+ tumor and cancer stem cells by targeting the MUC1 oncoprotein with configurational-specific monoclonal antibodies and peptides.

Nonmyeloablative conditioning with mesenchymal stem cell transplantation for type 1 diabetis mellitus. Background: MUC1, a glycoprotein overexpressed by breast, intestinal, pancreatic, and gastric ...
Business Wire

Minerva Biotechnologies - Overcoming the Solid Tumor Barrier: MUC1*-Targeted CAR T bearing 1XX mutations overcomes exhaustion and enables killing of low antigen expressing ...

WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies published “Effective CAR T cell targeting of a MUC1 cleavage product” in the Journal for ImmunoTherapy of ...
GEN

Humoral, Cellular Activity of MUC1 Vaccine Shrinks Tumors In Vivo

Candidate combines MUC1 glycopeptide with T-helper epitope and adjuvant. Scientists report on the design of an anticancer vaccine targeting MUC1, which triggers strong humoral and cellular immune ...
ascopubs.org

Inhibiting MUC1 a/b chain interaction mediates cytotoxicity of cells expressing MUC1: The MUC1 dyad oncoprotein as a functional target

Phase I trial of EC90 (keyhole-limpet hemocyanin fluorescein isothiocyanate conjugate) with GPI-0100 followed by EC 17 (folate- fluorescein isothiocyanate conjugate) in combination with ...
Yahoo Finance

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...
Business Wire

Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor ...

WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies, a private company developing 1 st-in-human therapies for the treatment of solid tumor cancers, announced today that the FDA has approved their ...
AZoNano

Optimizing Antigen Density on Gold Nanoparticles for Cancer Vaccines

MUC1 is a mucin protein overexpressed and abnormally glycosylated in many epithelial cancers. Although it is considered a potential target for vaccine development, its effectiveness is limited by its ...